drugset / Trial / NCT00758602

A Study of CellCept (Mycophenolate Mofetil) Combined With Tacrolimus and Corticosteroids in Kidney Transplant Patients.

NCT00758602

Phase 4 Completed 210 enrolled Hoffmann-La Roche
RandomizedParallel-groupOpen-labelTreatment

Summary

This 2 arm study will compare the efficacy and safety of CellCept, combined with low or standard dose tacrolimus plus corticosteroids, in patients with kidney transplants. Patients will be randomized into one of 2 groups to receive either 1)CellCept 2.0g/day po bid + tacrolimus 10-12ng/mL followed by a maintenance dose of 8-10ng/mL + corticosteroids or 2)CellCept 2.0g/day po bid + tacrolimus 8-10ng/mL in the first 2 months,3-7ng/mL in month 3 followed by a maintenance dose of 3-5ng/mL + corticosteroids. The anticipated time on study treatment is 1 year, and the target sample size is 100-500 individuals.

Timeline

Start
2008-09
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Mofetil Small molecule 0.75 g Oral
Subject Mycophenolate Mofetil Small molecule 1 g Oral
Subject Tacrolimus Small molecule 0.05 mg/kg Oral
Subject Tacrolimus Small molecule 0.08 mg/kg Oral
Subject Tacrolimus Small molecule 0.1 mg/kg Oral
Subject Tacrolimus Small molecule 0.15 mg/kg Oral
Background Prednisone Other / unclassified

Indications

No indication recorded.